SlidesetViral Hepatitis and Liver DiseaseRSVHIVDrug-drug interactions: All you need to know beyond www.hiv-druginteractions.org - Marta Boffito, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIV50% Adherence is enough with modern ARVS, right - Terrence Blaschke, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVThe ‘third wave’ of TB drug development what’s on the horizon (for patients with or without HIV) - Kelly Dooley, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVEfavirenz pharmacokinetics in HIV/TB coinfected persons initiating ART while receiving high dose rifapentine - Anthony Podany, PharmDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVIn silico design of a microarray patch as a multipurpose prevention technology - Rajith RajoliView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVThe initial Phase 1 evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254 - Samit Joshi, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVNovel antiviral and immune targets to cure HBV - Fabien Zoulim, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVImproved long acting drug delivery: What are the technologies - Andrew Owen, BSc, MSc, PhD, FSBView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVLong acting HIV drugs for treatment: Data and potential implementation - Charles Flexner, MDView Slideset
SlidesetRSVHIVViral Hepatitis and Liver DiseaseLong Acting HIV Drugs for Prevention: Data and Potential implementation - Laura Waters, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVClinical Case Presentation - Catia Marzolini, PharmD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVChanges in drug interaction profiles for first-line HIV therapy over the 20 years of the Liverpool Drug Interaction website - Sara GibbonsView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVEffect of CYP2b6 metabolizer status on levonorgestrel pharmacokinetics when combined with efavirenz-based antiretroviral therapy - Michelle PhamView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVDrugs abuse and chemsex a new challenge for antiretroviral drug-drug interaction - Tess MartinView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVDual Maintenance for HIV: Con Perspective - Andrew Hill, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVDual Maintenance for HIV: Pro Perspective - José Ramón Arribas, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVPopulation pharmacokinetics of VRC01 in infants and adults - Jerry LiView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVPharmacological treatment of NASH - Sven Francque, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInfectious disease action plan for the global accelerator for paediatric formulations (GAP-f) - Paul Domanico, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVPharmacokinetics of atazanavir boosted with cobicistat during pregnancy and postpartum - Jeremiah MomperView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInfant exposure to dolutegravir through placental and breastmilk transfer: A population PK analysis of DolPHIN-1 - Laura DickinsonView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVLow isoniazid concentrations in pregnant and postpartum women treated for tuberculosis irrespective of efavirenz-based ART co-treatment - Marije Van Schalkwyk, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVTenofovir-diphosphate in PBMC following increasing TAF vs. TDF dosing under directly observed therapy - Jenna YagerView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVAn exploration of adherence measures to detect recent changes in Truvada® dosing patterns - Daijha AndersonView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVPhysiologically based pharmacokinetic modelling to determine pharmacokinetic alterations driving ritonavir exposure changes in aging people living with HIV - Felix StaderView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVPhysiologically-based pharmacokinetic modeling of rilpivirine during pregnancy - Mary GockenbachView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVUtilization of physiologically based pharmacokinetic modelling (PBPK) to predict the effect of UGT enzyme inhibition and induction on the systemic exposure of Cabotegravir - Aarti PatelView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVCRISPR/Cas and gene editing for HIV - Paula Cannon, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVPharmacokinetics of tenofovir alafenamide 25 mg with PK boosters during pregnancy and postpartum - Kristina Brooks, PharmDView Slideset
SlidesetRSVHIVViral Hepatitis and Liver DiseaseSexual health clinic-based delivery model - Rena Janamnuaysook, MBAView Slideset
